vorinostat has been researched along with Leukemia, Lymphocytic, T Cell in 5 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ononye, SN | 1 |
| Vanheyst, MD | 1 |
| Giardina, C | 1 |
| Wright, DL | 1 |
| Anderson, AC | 1 |
| Daniel, KB | 1 |
| Sullivan, ED | 1 |
| Chen, Y | 1 |
| Chan, JC | 1 |
| Jennings, PA | 1 |
| Fierke, CA | 1 |
| Cohen, SM | 1 |
| Zhang, QL | 1 |
| Wang, L | 1 |
| Zhang, YW | 1 |
| Jiang, XX | 1 |
| Yang, F | 1 |
| Wu, WL | 1 |
| Janin, A | 1 |
| Chen, Z | 1 |
| Shen, ZX | 1 |
| Chen, SJ | 1 |
| Zhao, WL | 1 |
| Li, J | 1 |
| Liu, R | 1 |
| Lei, Y | 1 |
| Wang, K | 1 |
| Lau, QC | 1 |
| Xie, N | 1 |
| Zhou, S | 1 |
| Nie, C | 1 |
| Chen, L | 1 |
| Wei, Y | 1 |
| Huang, C | 1 |
| Ruefli, AA | 1 |
| Bernhard, D | 1 |
| Tainton, KM | 1 |
| Kofler, R | 1 |
| Smyth, MJ | 1 |
| Johnstone, RW | 1 |
5 other studies available for vorinostat and Leukemia, Lymphocytic, T Cell
| Article | Year |
|---|---|
Studies on the antiproliferative effects of tropolone derivatives in Jurkat T-lymphocyte cells.
Topics: Antineoplastic Agents; Cell Cycle; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screen | 2014 |
Dual-Mode HDAC Prodrug for Covalent Modification and Subsequent Inhibitor Release.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Cell Proliferation; Cells, Cultured; Chromatograp | 2015 |
The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis.
Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Synergism; Histone Deacetylase | 2009 |
Proteomic analysis revealed association of aberrant ROS signaling with suberoylanilide hydroxamic acid-induced autophagy in Jurkat T-leukemia cells.
Topics: Apoptosis; Autophagy; Gene Expression Regulation, Leukemic; Green Fluorescent Proteins; Humans; Hydr | 2010 |
Suberoylanilide hydroxamic acid (SAHA) overcomes multidrug resistance and induces cell death in P-glycoprotein-expressing cells.
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caspase 3 | 2002 |